当市场形势好的时候，制药企业拒绝生产外包因为它们认为这样做会有出现质量问题和泄露商业秘密的风险。
When times were good, drugs firms refused to outsource manufacturing because doing so, they argued, would result in quality problems and risk giving away trade secrets.
大型制药厂商将受益于此，因为它们所拥有营销机器和大量技术型销售人员能说服医生针对一种药品开出处方。
The big drugs companies will benefit from that because they have marketing machines and large technical sales forces to persuade doctors to prescribe a drug.
有人说肿瘤治疗药物相对缺乏的原因之一是因为对于制药公司来说他们无利可图。
Some claim that one reason for the relative absence of oncology drugs is that they are not profitable for pharmaceutical companies.
因为这些公司在其自身的行业里还是很强大的，所以它们将来可以找到新的出资人或者合作伙伴，可能是大型制药公司或者私募投资者。
Since these firms are strong in their field, they should be able to find new owners or partners with deep pockets, be they big pharma firms or private-equity investors.
诺华制药的老总魏思乐博士坚决拥护近来的并购。但是也承认大公司现在必须去公司外找灵感，因为“我们无法面面俱到。”
Dr Vasella, Novartis's boss, stoutly defends recent mergers, but accepts that big firms must now look outside for inspiration because “we can't do it all ourselves.”
即使呆得不耐烦了，史蒂夫也不能经常外出，因为他必须服用免疫抑制药物以防止新肝脏出现排斥反应。这使他的抵抗力变得脆弱。
Even if he felt up for it, Steve couldn't go out much because he had to take immunosuppressive medications to prevent rejection of the new liver, and this made him more susceptible to disease.
不过，因为不知多少疫苗已经被买得起的国家和制药厂签订采购合同预订了，这些计划实现起来也许有些困难。
That may be difficult to realize, however, because an unknown number of doses is already tied up through contracts between pharmaceutical companies and countries that can afford them.
而这又会让你感到害怕，因为你生产了这么好的产品，却不像制药业，你并不能够对医疗仪器有太多的专利保护。
It scares the Jesus out of you, cause you've got this great product,unlike pharmaceuticals, you don't have much patent protection in medical devises.
特别令人关注的是这家制药巨头受到美元走强的打击，因为该公司54%的销售额来自海外市场。
The giant drugmaker has taken a hit from the stronger dollar, a particular concern for the company because 54% of its sales come from foreign markets.
在少数情况下，医生可能会因为严重的医学问题比如肿瘤或致命感染而让移植受者停用免疫抑制药物。
In rare cases, a physician may stop a transplant recipient's immunosuppressive drugs because of a serious medical problem such as cancer or life-threatening infection.
之所以这样说是因为制药企业有大量而可靠的现金来源。
One reason to think so is that the pharmaceutical industry is known for its large, reliable cashflows.
但他也表示，这次他非常谨慎地看待新仿制药物的前景，因为生物技术药物很难仿制。
But he also said he was more cautious about the promise of generics this time, because biotech medicines were not easy to copy.
病例检出率低意味着数据不足，这也意味着药物预测性差以及缺乏对制药商的激励措施，因为制药商往往是应需求生产药物。
Poor case detection means poor data, and this means poor drug forecasting and weak incentives for manufacturers, who tend to produce on demand.
然而，在通常情况下，第一个仿制药并不能在市场上自由的销售，因为专利所有人都会采取销售品牌药物的“授权”仿制药的措施进行干扰。
Often, however, the first generic does not have a free run, because patent-owners have taken to selling "authorised" generic versions of branded pills.
因为在辉瑞制药与百康制药的合作中显示，双方都可能需要合作伙伴。
As the Pfizer deal with Biocon suggests, both sides may need partners.
Mossialos认为，新型抗生素研发的不足很大程度上是因为抗生素不像其他商品一样能够使制药公司获利。
Mossialos said the lack of development of new antibiotics is largely because antibiotics don't earn pharmaceutical companies as much as other products.
“对制药商来说，它们并不是一个机会，因为这些药物对孩子来说没效，”他说。
"They're not an opportunity for drug makers because the drugs have not been shown to be effective for children," he said.
这一趋势还将继续，因为制药巨头们正面临更新产品线放缓以及未来几年许多药物专利到期的形势。
The trend only looks to continue as the global pharmaceutical industry faces slower pipelines and significantly more drugs come off patent in the next few years.
根据派普和同事在《细胞》(Cell)期刊上发表的报告，因为与Medivation和辉瑞制药的实验性阿斯海默症治疗药物Dimebon 成份相似，这种化合物有可能提供更多改善该药药效的方法。
The compound is similar to Medivation Inc and Pfizer Inc's experimental Alzheimer's drug, Dimebon, and may provide ways to improve its effects, Pieper and colleagues reported in the journal Cell.
20年的专利保护对于制药业来说也许有些道理，因为药物实验和把药物带入市场可能要花费十多年时间。
Protection for 20 years might make sense in the pharmaceutical industry, because to test a drug and bring it to market can take more than a decade.
我们把该列表交给了大学，制药厂，生物科技公司，开始开发新的药物，因为这些突变基因及其蛋白质是新的治疗靶点。
We hand that list over to the universities, the pharmaceuticals, the biotech companies to start developing new drugs because those mutated genes and their proteins are targets for new therapeutics.
传染科医生：我认为医生不会因为制药公司的影响而做出危险的决定。
Dr. Virus: I don't think that doctors make dangerous decisions because of the influence of the drug companies.
传染科医生：我认为医生不会因为制药公司的影响而做出危险的决定。
Dr. Virus: I don't think that doctors make dangerous decisions because of the influence of the drug companies.
应用推荐